Various advances have been made in the understanding and diagnosis of axial spondyloarthritis (axSpA). In some cases, these advances have led to the introduction of new treatments for patients with axSpA.

Ongoing research is helping to shed light on how to use existing and new treatments for this condition, according to the authors of a review published by Rheumatology.

Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: What, when and how?Rheumatology. 2020. 59(suppl 4):iv79–iv89.

A better understanding will aid in clinical decision-making for these patients and in the development of treatment recommendations.

 

 

Background of axSpA

 

To treat axSpA, an understanding of the disorder’s trajectory is imperative. This disease often begins when a person is in their 30s, with men at slightly higher risk.

Many—but not all—patients with axSpA will progress from the non-radiographic to the radiographic form over time. The inflammation begins at the level of the SIJ and can extend to other parts of the spine, thus causing inflammatory and structural changes.

Poddubnyy D, Sieper J. Treatment of axial spondyloarthritis: What does the future hold?Curr Rheumatol Rep. 2020;22(9):47.

The structural changes on x-ray can take years to form, and once they are present, they are irreversible. 

 

 

Treatment categories

The long-term suppression of inflammation can attenuate the radiographic progression of axSpA. There are four broad categories for the treatment of axSpA:

• Exercise and physical therapy

• NSAIDs, which have been available since the 1950s

• TNF inhibitors, which were first approved in 2003

• IL-17 inhibitors, which were first approved in 2016

Following a lull in drug development after the TNF inhibitors, axSpA treatment has expanded with the introduction and approval of two new classes of drugs: IL-17A and JAK inhibitors. There are also several new treatments in phase 3 trials, according to research published by Nature Reviews Rheumatology.

Danve A, Deodhar A. Treatment of axial spondyloarthritis: An update. Nat Rev Rheumatol. 2022;18(4):205–216.

 

 

Immunotherapy

Additionally, the efficacy of IL-17A inhibition is supported by compelling data and points at the central role of the IL-23/IL-17 pathway in spondyloarthritis (SpA) pathogenesis.

The exact mechanism of JAK inhibitors in treating axSpa is not yet known but probably involves the IL-23/IL-17 axis in which several key cytokines function in the JAK-STAT pathway. JAKs are intracellular enzymes that modulate hematopoiesis and immune-cell function.

RINVOQ® (upadacitinib) extended-release tablets, for oral use [package insert]. North Chicago, IL: AbbVie; January 2022.

 

“The JAK/STAT pathway is involved in the signaling of several inflammatory players implicated in the pathogenesis of axSpA,” concluded the author of a review published in Pharmaceuticals.

Toussirot E. The use of Janus Kinase inhibitors in axial spondyloarthritis: Current insights. Pharmaceuticals (Basel). 2022;15(3):270.

“Clinical trials of JAKi [JAK inhibitors] in axSpA have yielded favorable results in key clinical domains of the disease, with an acceptable safety profile."  

 

Targeting JAK is thus an attractive and novel therapeutic intervention in this inflammatory rheumatic disease.

As of February 2023, upadacitinib is approved to treat radiographic and non-radiographic axSpA.

Upadacitinib (Rinvoq) approved for non-radiographic axial spondyloarthritis. Spondylitis Association of America. November 4, 2022.

Where this agent fits into the treatment strategy of axSpA (eg, first-line, second-line, third-line) remains to be elucidated, per the Pharmaceuticals review.

 

 

Prescribing biologics

When prescribing biologic DMARDs (bDMARDs), physicians should consider how likely it is that the patient will respond to the treatment. 

It is particularly important to treat such patients to prevent erosion and bone formation that are essentially irreversible. 

Other features associated with higher response rates include younger age, shorter disease duration, elevated CRP, and certain inflammatory MRI features. Obesity and smoking, however, are tied to decreased response.

Authors of the review published in Rheumatology further clarified the role of these risk factors.

“These factors are not entirely surprising; the predictors of ‘good response’ essentially reflect a higher likelihood of the patient truly having active inflammatory axSpA, as opposed to other causes of back pain. Therefore, careful clinical assessment and consideration prior to commencing biologics and, again in those who fail to respond to a particular bDMARD, is a crucial part of decision making," the authors wrote.

“Simply applying classification criteria and following treatment guidance using a pre-defined checklist or algorithm approach is not appropriate for clinical practice; the latter requires thoughtful exclusion of other potential causes (such as degenerative disc disease, fibromyalgia) for the patient’s symptoms, which are unlikely to respond to biologics and which require different management strategies,” they added.

 

Further considerations

 

There are evidence-based guidelines for the treatment of axSpA, including those from ACR–SAA–SPARTAN and ASAS–EULAR. These guidelines are fairly uniform and offer practical approaches to the management of this disease, according to the Nature Reviews Rheumatology research.

While multidisciplinary care is not routine for this disease, when administered, it should include input from rheumatologists, radiologists, orthopedists, primary care, physical therapy, and psychiatry.